このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

リラグルチド投与中の肥満患者の動脈硬化に対するさまざまな食事の影響

2026年11月3日 更新者:Marlene Chakhtoura、American University of Beirut Medical Center

リラグルチドの肥満患者の動脈硬化に対する地中海式、低炭水化物/高タンパク質および低脂肪食の効果:無作為対照試験

In patients initiating Semaglutide for weight management, the objective is to compare the effect of the Mediterranean diet and the high protein/low carbohydrate (HP/LC) diet CV parameters, namely arterial stiffness, measured by carotid-femoral pulse wave velocity (cfPWV), and visceral adipose tissue, in addition to other metabolic indicators.

調査の概要

詳細な説明

This is a 6-month open label pilot RCT that will be conducted on Lebanese subjects with obesity, upon the initiation of Semaglutide for medical weight management, as recommended by their physician. Patients will be randomized to 2 treatment arms: Med diet and HP/LC diet. Med diet will be hypocaloric, allowing the same energy restriction, of 500 Kcal/d, while the HP/LC diet will be ad libitum. Participants will be recruited from the Endocrine clinics at AUB-MC, and from satellite clinic next in Beirut. Brochures and posters of the trial will be available in the clinic waiting areas. Patients of both participating and non-participating physicians will be recruited in the study.

研究の種類

介入

入学 (実際)

31

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Riad El Solh
      • Beirut、Riad El Solh、レバノン、1107 2020
        • American University of Beirut - Medical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~49年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Men and premenopausal women, 18-49 years, with obesity defined as BMI ≥ 30 kg/m2
  • Upon the initiation of Semaglutide (within the first 1-4 weeks) for medical weight management, for clinical purposes, as advised by the primary physician
  • Able to commit for a 6-month trial visits

Exclusion Criteria:

  • Pregnant women
  • Patients who are taking or have taken other weight reducing drug therapies in the previous 6 months
  • Patients who have undergone metabolic weight loss surgery
  • Patients known to have diabetes (HbA1c ≥6.5% at screening)
  • Patients with uncontrolled hypertension
  • Patients with uncontrolled cardiac disease, pulmonary, renal or liver diseases, active cancer or psychiatric diseases
  • Patients with excessive alcohol intake, defined as ≥ 2 glasses per day
  • Patients known to have uncontrolled/ untreated thyroid disorders.
  • Patients with cushing disease or polycystic ovaries, and those with neuro-endocrine or drug induced obesity (such as anti-psychotic, steroids, hormonal therapy): Such patients are resistant to weight loss, and they need treatment of their primary disease and/or cessation of the culprit medication to lose weight
  • Patients with untreated gout
  • Patients who have undergone bariatric surgery

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Mediterranean Diet

30 participants will be randomized to this arm. The intervention consists of 8 visits, over a period of 24 weeks, including 6 individual educational sessions on Mediterranean diet in patients on Semaglutide and 2 reinforcement educational sessions towards the end of the trial. Dietary assessments and adherence questionnaires will be conducted on several visits to assess adherence.

The diet will consist of a calorie-restricted Med diet, with 500 Kcal/d energy restriction. The intervention consists of individual and reinforcement sessions on Med diet. During these sessions, the RA will go over the benefits of Med diet, what composition it should have, and how to make appropriate choices for meal planning, in addition to providing food lists, by season. The individual sessions with subjects will also allow to individualize the diet plan.

実験的:High Protein/Low Carbohydrate Diet

30 participants will be randomized to this arm. The intervention consists of 8 visits, over a period of 24 weeks, including 6 individual educational sessions on High Protein/Low Carbohydrate diet in patients on Semaglutide and 2 reinforcement educational sessions towards the end of the trial. Dietary assessments and adherence questionnaires will be conducted on several visits to assess adherence.

This is a non-ketogenic diet consisting of ad libitum intake of proteins, fat, and vegetables, with restriction of daily carbohydrates to <130 g/d. The intervention consists of individual and reinforcement educational sessions on HP/LC, same as with Med diet (above). The individual sessions with subjects will also allow to individualize the diet plan.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
cfPWV measurement and pulse wave analysis (PWA) using SphygmoCorCvMS V9 (AtCor Medical)
時間枠:6 months after enrollment

Measured by an RA or a technician, based on the American Heart Association Council recommendations on arterial stiffness measurement in research. The distance from the suprasternal notch to the carotid pulse, and to the femoral site on the same side will be measured; the former distance is subtracted from the latter one. Ten seconds of carotid and 10 seconds of femoral arterial waveforms will be recorded, and the average of the data will be obtained for each of the sites.

6 months after enrollment

二次結果の測定

結果測定
メジャーの説明
時間枠
Body composition - visceral adipose tissue using dual x-ray absorptiometry (DXA)
時間枠:6 months after enrollment

Measured by an RA or a technician, assessed using dual x-ray absorptiometry (DXA), Hologic machine, version 13.6.0.5, the preferred method for the assessment of body composition. The ISCD recommendations will be followed for body composition measurement.

6 months after enrollment
Body composition - percent fat-free body mass using dual x-ray absorptiometry (DXA)
時間枠:6 months after enrollment

Measured by an RA or a technician, assessed using dual x-ray absorptiometry (DXA), Hologic machine, version 13.6.0.5, the preferred method for the assessment of body composition. The ISCD recommendations will be followed for body composition measurement.

6 months after enrollment
Body composition - percent body fat using dual x-ray absorptiometry (DXA)
時間枠:6 months after enrollment

Measured by an RA or a technician, assessed using dual x-ray absorptiometry (DXA), Hologic machine, version 13.6.0.5, the preferred method for the assessment of body composition. The ISCD recommendations will be followed for body composition measurement.

6 months after enrollment

その他の成果指標

結果測定
メジャーの説明
時間枠
Dietary Assessment using 24-hour recalls
時間枠:6 months after enrollment

Three-repeated 24-hour recalls (24 HR) administered via phone (2-week days and one week-end day, during one specific week). During the phone call, the participant will be asked to recall all what she/he has consumed during the past 24 hours, and the multiple pass approach of the USDA will be adopted.

6 months after enrollment
Dietary Assessment using adherence questionnaires
時間枠:6 months after enrollment

During the individual sessions, brief adherence assessment questionnaires for each diet, adapted from PREDIMED protocol, will be administered to calculate dietary adherence scores.

6 months after enrollment
Anthropometric measurements - weight in kilograms, height in centimetres, aggregated into BMI (kilogram per meter squared).
時間枠:6 months after enrollment

Weight and height will be measured following standard operating procedures (SOP) and BMI will be computed by dividing weight by height squared.

6 months after enrollment
Anthropometric measurements - waist and hip circumference in centimetres, aggregated into waist to hip ratio ratio
時間枠:6 months after enrollment

Waist and hip circumference will be measured following standard operating procedures (SOP).

6 months after enrollment
Vital signs - blood pressure
時間枠:6 months after enrollment

Blood pressure will be measured following standard operating procedures (SOP).

6 months after enrollment
Vital signs - heart rate
時間枠:6 months after enrollment

Heart rate will be measured following standard operating procedures (SOP).

6 months after enrollment
Genetic studies
時間枠:6 months after enrollment

Genetic studies will consist of Single Nucleoside Polymorphism (SNP) analysis of genes of the GLP1 receptors and cannabinoid receptor 1 will be performed in the molecular lab. These tests will be run at the endocrine core research Lab in batches at study completion.

6 months after enrollment
Metabolic, inflammatory and appetite hormones in pg/mL
時間枠:6 months after enrollment

Gastric inhibitory polypeptide (GIP), Leptin, Adiponectin, Orexin, IL6. These tests will be run at the endocrine core research Lab in batches at study completion.

6 months after enrollment
Metabolic, inflammatory and appetite hormones in pmol/L
時間枠:6 months after enrollment

Insulin and Ghrelin.These tests will be run at the endocrine core research Lab in batches at study completion.

6 months after enrollment
Metabolic, inflammatory and appetite hormones in ng/mL
時間枠:6 months after enrollment

Irisin and mineral hormones and markers, including Crosslaps, Osteocalcin, GLP1. These tests will be run at the endocrine core research Lab in batches at study completion.

6 months after enrollment
Quality of Life Measurement as assessed by the SF-36 questionnaire
時間枠:6 months after enrollment

SF-36 questionnaire filled by participant

6 months after enrollment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Marlene Chakhtoura, MD, MSc、American University of Beirut Medical Center

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年7月1日

一次修了 (実際)

2025年12月15日

研究の完了 (実際)

2025年12月15日

試験登録日

最初に提出

2021年7月2日

QC基準を満たした最初の提出物

2021年7月26日

最初の投稿 (実際)

2021年8月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月5日

QC基準を満たした最後の更新が送信されました

2026年11月3日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する